December 1, 2017 Regulatory InDex Pharmaceuticals reports new mechanism of action data for cobitolimod Read more
November 17, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – September 2017 Read more
November 16, 2017 Non Regulatory InDex Pharmaceuticals Holding AB (publ) announces Nomination Committee and financial reporting dates for 2018 Read more
October 26, 2017 Non Regulatory InDex Pharmaceuticals will participate in the United European Gastroenterology Week (UEGW) Read more
August 25, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – June 2017 Read more
August 9, 2017 Non Regulatory InDex Pharmaceuticals receives orphan-drug designation for pediatric ulcerative colitis in the US Read more
June 21, 2017 Regulatory InDex Pharmaceuticals enrolls first patient in the phase IIb study CONDUCT with cobitolimod Read more
May 30, 2017 Regulatory Bulletin from Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 30, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2017 Read more
May 5, 2017 Non Regulatory InDex Pharmaceuticals will participate in the Digestive Disease Week (DDW) Read more
April 27, 2017 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
April 27, 2017 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2016 Read more
March 22, 2017 Non Regulatory InDex Pharmaceuticals concludes well attended Investigators’ Meeting for the phase IIb study CONDUCT Read more
March 14, 2017 Regulatory InDex Pharmaceuticals gets patent for additional DIMS compounds granted in the US Read more
February 1, 2017 Regulatory InDex Pharmaceuticals enters agreement with CRO for the CONDUCT study Read more
January 23, 2017 Non Regulatory InDex Pharmaceuticals will participate in the European Crohn’s and Colitis Organisation (ECCO) Congress Read more